Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes

We read with great interest the observations made by Montalvo-Gordon and colleagues regarding the potential of SGLT-2 inhibitors to ameliorate ascites and peripheral edema in patients with cirrhosis and concomitant type 2 diabetes mellitus (T2DM), serving also as an alternative treatment option in patients with diuretic-resistant or diuretic-intractable ascites. Interestingly, all 3 patients remained free of ascites and edema 12-26 months after diuretics' discontinuation, replaced by a SGLT-2 inhbitor.